OKYO Pharma Limited (OKYO)
NASDAQ: OKYO · Real-Time Price · USD
1.660
-0.030 (-1.78%)
At close: Mar 6, 2026, 4:00 PM EST
1.650
-0.010 (-0.60%)
After-hours: Mar 6, 2026, 7:25 PM EST
OKYO Pharma Employees
OKYO Pharma had 4 employees as of March 31, 2025. The number of employees increased by 1 or 33.33% compared to the previous year.
Employees
4
Change (1Y)
1
Growth (1Y)
33.33%
Revenue / Employee
n/a
Profits / Employee
-$1,153,335
Market Cap
85.27M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Champions Oncology | 213 |
| Pliant Therapeutics | 171 |
| Seres Therapeutics | 103 |
| Verrica Pharmaceuticals | 71 |
| aTyr Pharma | 65 |
| PMV Pharmaceuticals | 47 |
| Pyxis Oncology | 44 |
| Cognition Therapeutics | 28 |
OKYO News
- 12 days ago - OKYO Abstract Selected for Presentation at Premier Global Ophthalmology Congress - GlobeNewsWire
- 23 days ago - OKYO Pharma Announces Pricing of $20 Million Public Offering of Ordinary Shares - GlobeNewsWire
- 23 days ago - OKYO Pharma Announces Public Offering of Ordinary Shares - GlobeNewsWire
- 24 days ago - OKYO Pharma Announces Transition of At-The-Market Equity Offering Facility to Leerink Partners - GlobeNewsWire
- 25 days ago - OKYO Pharma Strengthens World Class Leadership Team with Appointment of Flavio Mantelli, MD, PhD as Chief Medical Officer - GlobeNewsWire
- 5 weeks ago - OKYO Pharma Announces Acceptance of Urcosimod Phase 2 Study Results for Presentation at Prestigious ASCRS Annual Meeting - GlobeNewsWire
- 5 weeks ago - OKYO Pharma Announces Successful Type C Meeting with the FDA - GlobeNewsWire
- 6 weeks ago - FDA Approves Compassionate Use of Urcosimod (0.05%) for the Treatment of Neuropathic Corneal Pain - GlobeNewsWire